00:00 (upbeat music)
00:01 Colorectal cancer is the third most common cancer worldwide.
00:04 And although the majority of colorectal cancer cases
00:06 have historically occurred in individuals age 45 and older,
00:09 it is increasingly affecting younger people.
00:12 Alarming statistics reveal that new cases
00:14 of colorectal cancer in individuals under the age of 50
00:17 have been steadily rising over the past few decades.
00:20 Colorectal cancer is now the leading cause
00:22 of cancer death for Americans
00:23 between the ages of 20 and 59 years old,
00:26 according to the National Cancer Institute.
00:29 However, younger adults are not routinely screened
00:31 for colorectal cancer as it is still relatively uncommon
00:34 in their age group.
00:35 Determining the exact reasons for this uptake
00:37 remains a challenge,
00:38 although many experts believe this trend
00:40 is being driven by a sedentary lifestyle,
00:42 obesity, smoking, heavy alcohol use, low fiber,
00:46 high fat diets or diets high in processed meats
00:48 and other environmental factors.
00:51 However, even without absolutely clear answers,
00:53 regular screening is crucial to early detection
00:56 followed by highly successful treatment
00:58 of colorectal cancer.
00:59 The CDC reports that colorectal cancer
01:02 is the second most fatal cancer
01:03 in the United States and Europe.
01:05 However, it is also the most preventable
01:07 with early detection leading to survival rates above 90%.
01:11 Given the rising incidence in young individuals
01:13 and the majority's lack of regular screenings
01:15 until later in life,
01:16 accessible screenings are more important than ever.
01:19 By providing efficient and convenient methods
01:21 for early detection,
01:22 healthcare professionals can make significant progress
01:25 in combating colorectal cancer
01:27 and ultimately save countless lives.
01:29 Mainz Biomed, a company that specializes
01:32 in developing molecular genetic diagnostic solutions
01:34 for life-threatening conditions,
01:36 has created ColoAlert, an innovative product
01:38 that addresses the need for easier
01:40 and more accessible cancer screenings
01:41 for quick detection and treatment of colorectal cancer.
01:44 This non-invasive and user-friendly test
01:46 aims to make colorectal cancer screening fast,
01:49 simple and precise.
01:50 The test is the first DNA-based screening test
01:53 for colorectal cancer in Europe.
01:55 ColoAlert has been recommended
01:56 by the US Preventative Services Task Force
01:58 to all DNA tests such as ColoAlert
02:00 should be conducted once every three years,
02:02 starting at age 45.
02:04 Every year, 16.6 million colonoscopies
02:07 are performed in the US alone,
02:08 and yet one third of US residents aged 50 to 75
02:11 have never been screened for colon cancer.
02:14 Many times, fear of a colonoscopy
02:16 contributes to populations avoiding the screening.
02:18 ColoAlert is a non-invasive solution
02:20 to the longstanding apprehension.
02:23 Simply put, this innovative screening tool
02:25 is not limited to younger ages.
02:26 In fact, ColoAlert may have annual market opportunity
02:29 of around $3.7 billion in the US
02:32 for testing populations aged 50 and above
02:35 every three years as recommended by the FDA.
02:38 ColoAlert's unique genetic profiles
02:40 allow for tailored treatment for each individual patient,
02:42 leading to better health outcomes
02:44 for patients with colorectal cancer.
02:46 This revolutionary product is a major stride
02:48 in combating colorectal cancer
02:49 and has the potential to save countless lives.
02:52 Maine's Biomed is quickly emerging
02:54 as a strong contender in the diagnostic industry,
02:56 putting renowned companies like Xact Sciences
02:59 and Genoscopy on notice.
03:00 While both Xact Sciences and Genoscopy
03:03 utilize DNA and RNA biomarkers respectively,
03:06 Maine's Biomed is breaking new ground
03:07 by revolutionizing the field with its cutting-edge evolution
03:11 of groundbreaking patent-pending mRNA biomarkers.
03:14 This is evident by the company's ColoAlert
03:16 recent success in the market.
03:18 The revenues generated by ColoAlert
03:20 in the first half of 2023
03:21 surged by an impressive 108%
03:23 when compared to the same period in 2022.
03:26 This remarkable growth further solidifies
03:28 Maine's Biomed's position in the industry
03:30 and showcases its ability to develop groundbreaking products
03:33 that meet the needs of healthcare professionals
03:35 and patients alike.
03:36 With its pioneering approach and revenue growth
03:38 over H1 this year,
03:40 Maine's Biomed seems poised to disrupt the market
03:42 and establish itself as a trusted and innovative provider
03:45 of molecular genetic diagnostic solutions.
03:48 Their commitment to pushing the boundaries
03:49 of diagnostic technology and growth trajectory
03:52 seems to be making them a force to be reckoned with
03:54 in the industry,
03:55 setting them apart from their competitors.
03:57 (upbeat music)
Comments